Trials / Terminated
TerminatedNCT02656303
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination With Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to provide the opportunity to the participants who progressed on treatment arm previously in the study UTX-TGR-304 (NCT02612311) to receive ublituximab (TG-1101) treatment in combination with umbralisib (TGR-1202).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ublituximab | Ublituximab IV infusion |
| DRUG | Umbralisib | Umbralisib tablets |
Timeline
- Start date
- 2016-01-07
- Primary completion
- 2022-05-26
- Completion
- 2022-07-11
- First posted
- 2016-01-14
- Last updated
- 2023-06-22
- Results posted
- 2023-06-22
Locations
87 sites across 4 countries: United States, Italy, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02656303. Inclusion in this directory is not an endorsement.